ECAGITATUG REZETECAN
UNII KJB5FV35JK

Substance Identification & Data

This profile provides standardized clinical and technical data for Ecagitatug Rezetecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) KJB5FV35JK.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3076369-08-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

KJB5FV35JK

CAS Registry Number

3076369-08-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ECAGITATUG REZETECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

14075

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Ecagitatug Rezetecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ecagitatug Rezetecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Ecagitatug Rezetecan

Common Names & Synonyms

H-gamma2 heavy chain (1-446) [VH (Homo sapiens IGHV3-30-5*03 (82.7%) -(IGHD) -IGHJ4*01 (92.3%) L123>T (115), CDR-IMGT [8.7.14] (26-33.51-57.96-109)) (1-120) -Homo sapiens IGHG2*01 (100%) G2m.. CH2 V45.1 (CH1 (121-218), hinge 1-12 (219-230), CH2 V45.1 (281) (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-218')-disulfide with Lkappa light chain (1'-218') [V-KAPPA Musmus/Homsap (Mus musculus IGKV3-12*01 (81.8%) -IGKJ1*02 (90.9%) G120>Q (104')/Homo sapiens IGKV4-1*01 (79.2%) -IGKJ2*01 (100%), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (157'), V101 (195')) (112'-218')]; dimer (222-222'':223-223'':226-226'':229-229'')-tetrakisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHOK1SV, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa; substituted at the sulfur atoms of 5.3 L-cysteinyl residues on an average among 134, 222, 223, 226, 229, 218', 134'', 222'', 223'', 226'', 229'' and 218''' with (3RS)-1-[(2R,10S)-10-benzyl-2-cyclopropyl-1-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12Hbenzo[ de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino}-1,6,9,12,15,18-hexaoxo-3-oxa-5,8,11,14,17-pentaazatricosan-23-yl]-2,5-dioxopyrrolidin-3-yl (rezetecan) groups

Immunoglobulin G2, anti-(Human hepatocyte growth factor receptor c-Met) (human-Mus musculus monoclonal SHR-1826 γ2-chain), disulfide with human-Mus musculus monoclonal SHR-1826 κ-chain, dimer, reduced, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[(1R)-1-cyclopropyl-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide

ecagitatug rezetecan [INN]

External Clinical & Regulatory Resources

Previous UNIIKJB3VO906F

Next UNIIKJC3826558